Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)

por Dhainaut, J, Antonelli, M, Wright, P, Belger, M, Cobas-Meyer, M, Mignini, M, Janes, J
Publicado 2008